Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Risankizumab (Synonyms: SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066)

Catalog No. T76778 Copy Product Info
🥰Excellent
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Risankizumab

Copy Product Info
🥰Excellent
Catalog No. T76778
Synonyms SKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066

Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.

Risankizumab
Cas No. 1612838-76-2
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$243In StockIn Stock
5 mg$793-In Stock
10 mg$1,230-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95.3% (SDS-PAGE); 98.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Risankizumab (BI 655066) is a humanized IgG monoclonal antibody (Kd <10 pM) targeting the IL-23 p19 subunit. It inhibits IL-17 production induced by human IL-23 in mouse splenocytes with an IC50 value of 2 pM. Risankizumab is used for the prevention and treatment of immune and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis, and erythrodermic psoriasis.
Targets&IC50
IL-17:2 pM (human), IL-23:10pM (kd,cynomolgus), IL-17:17 pM (cynomolgus), IL-23:10pM (kd,human)
In vitro
With Kds <10 pM, Risankizumab (BI 655066) exhibits high affinity for human and cynomolgus IL23[3]. Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively[2].
In vivo
In mice, Risankizumab (BI 655066) inhibits IL23-induced ear swelling and cytokine production following a single intraperitoneal (i.p.) dosage of 1 mg/kg[2].
SynonymsSKYRIZI, Risankizumab rzaa, BI-655066, ABBV 066
Reactivity
Human
Verified Activity
Immobilized Human IL-23 Protein (His) (TMPY-00406) at 1 μg/mL (100 μL/well) can bind Risankizumab. The EC50 is 9.40 ng/mL.
verifiedActivity
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetIL-23a
Chemical Properties
Molecular Weight145.85 kDa
Cas No.1612838-76-2
Antibody Information
IsotypeHuman IgG1 kappa
Recommended Isotype Control
Storage & Solubility Information
Storage-20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Risankizumab | purchase Risankizumab | Risankizumab cost | order Risankizumab | Risankizumab chemical structure | Risankizumab in vivo | Risankizumab in vitro | Risankizumab molecular weight